oa SA Pharmaceutical Journal - Biological drugs in breast cancer : increasing understanding for the pharmacist : review
|Article Title||Biological drugs in breast cancer : increasing understanding for the pharmacist : review|
|© Publisher:||Medpharm Publications|
|Journal||SA Pharmaceutical Journal|
|Affiliations||1 Amayeza Info Centre|
|Publication Date||Sep 2014|
|Pages||24 - 27|
|Keyword(s)||Bevacizumab, Biological drugs, Breast cancer, Lapatinib, Novel therapeutic agents and Trastuzumab|
Cancer in South Africa is an emerging health problem, with breast cancer being a leading cancer in women. The medical treatment of breast cancer was solely reliant on cytotoxic chemotherapy for many years. A greater understanding of the underlying biology of breast cancer has resulted in the identification of a number of molecular targets and the development of novel therapeutic agents. Thus, treatment has evolved over the past decade into a more target-directed approach with the use of biological drugs. The three currently available biological drugs registered in South Africa for use in breast cancer include trastuzumab (Herceptin®), bevacizumab (Avastin®) and lapatinib (Tykerb®). This article briefly discusses their role in targeting breast cancer.
Article metrics loading...